Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis

Clinics in Liver Disease

Volumn 8, Issue 4, 2004, Pages 861-879

  Harrison, Stephen A ^a   Neuschwander Tetri, Brent A ^b  

^a BROOKE ARMY MEDICAL CENTER   (United States)

^b SAINT LOUIS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ALLOPURINOL; ALPHA TOCOPHEROL; AMINOTRANSFERASE; AMIODARONE; APOLIPOPROTEIN E; ASCORBIC ACID; ASPARTATE AMINOTRANSFERASE; ATORVASTATIN; BETAINE; CERULOPLASMIN; CORTICOSTEROID; GEMFIBROZIL; HALOTHANE; ISONIAZID; METFORMIN; METHOTREXATE; METHYLDOPA; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PIOGLITAZONE; ROSIGLITAZONE; TAMOXIFEN; TETRACYCLINE; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; URSODEOXYCHOLIC ACID; VALPROIC ACID; VERY LOW DENSITY LIPOPROTEIN;

ANAMNESIS; APOPTOSIS; BARIATRIC SURGERY; CELL DEATH; CERULOPLASMIN BLOOD LEVEL; CLINICAL FEATURE; CLINICAL TRIAL; DIAGNOSTIC IMAGING; DISEASE COURSE; DISEASE SEVERITY; DNA POLYMORPHISM; ENZYME ACTIVITY; ETHNIC DIFFERENCE; FATTY ACID OXIDATION; GENE MUTATION; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; HEREDITY; HUMAN; HYPERLIPIDEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; IRON OVERLOAD; LABORATORY TEST; LIPOGENESIS; LIPOLYSIS; LIVER BIOPSY; LIVER CELL; LIVER CIRRHOSIS; LIVER FIBROSIS; MATURITY ONSET DIABETES MELLITUS; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; ONSET AGE; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; PATHOGENESIS; PHYSICAL EXAMINATION; PROTEIN PHOSPHORYLATION; PROTEOMICS; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; WEIGHT REDUCTION;

CHRONIC DISEASE; DIABETES COMPLICATIONS; FATTY LIVER; HEPATITIS; HUMANS; INCIDENCE; INSULIN RESISTANCE; OBESITY; PREVALENCE;

EID: 4744347827     PISSN: 10893261     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cld.2004.06.008     Document Type: Review

References (138)

1. J.O. Westwater, and D. Fainer Liver impairment in the obese Gastroenterology 34 1958 686 693
2. R.L. Peters, T. Gay, and T.B. Reynolds Post-jejunoileal bypass hepatic disease. Its similarity to alcoholic hepatic disease Am J Clin Pathol 63 3 1975 318 331
3. M. Adler, and F. Schaffner Fatty liver hepatitis and cirrhosis in obese patients Am J Med 67 1979 811 816
4. J. Ludwig, T.R. Viggiano, D.B. McGill, and B.J. Oh Nonalcoholic steatohepatitis: Mayo clinic experience with a hitherto unnamed disease Mayo Clin Proc 55 1980 434 438
5. W. Youssef, and A.J. McCullough Diabetes mellitus, obesity, and hepatic steatosis Sem Gastrointest Dis 13 2002 17 30
6. H. Nomura, S. Kashiwagi, J. Hayashi, W. Kajiyama, S. Tani, and M. Goto Prevalence of fatty liver in the general population of Okinowa, Japan Jpn J Med 27 1988 142 149
7. S. Bellentani, C. Tiribelli, G. Saccoccio, M. Sodde, N. Fratti, and C. De Martin Prevalence of chronic liver disease in the general population of northern Italy: the Dyonisos study Hepatology 20 1994 1442 1449
8. I.R. Wanless, and J.S. Lentz Fatty liver hepatitis (steatohepatitis) and obesity: an autopsy study with analysis of risk factors Hepatology 12 1990 1106 1110
9. C. Garcia-Monson, E. Martin-Perez, O.L. Iacono, M. Fernandez-Bermejo, P.L. Majano, and A. Apolinario Characterization of pathogenic and prognostic factors of nonalcoholic steatohepatitis associated with obesity J Hepatol 33 2000 716 724
10. L. Spaulding, T. Trainer, and D. Janiec Prevalence of nonalcoholic steatohepatitis in morbidly obese subjects undergoing gastric bypass Obes Surg 13 2003 347 349
11. J.B. Dixon, P.S. Bhathal, and P.E. O'Brien Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese Gastroenterology 121 2001 91 100
12. A. Franzese, P. Vajro, A. Argenziano, A. Puzziello, M.P. Iannucci, and M.C. Saviano Liver involvement in obese children: ultrasonography and liver enzymes levels at diagnosis and during follow-up in an Italian population Dig Dis Sci 42 1997 1428 1432
13. K. Tominaga, J.H. Kurata, Y.K. Chen, E. Fujimoto, S. Miyagawa, and I. Abe Prevalence of fatty liver in Japanese children and relationship to obesity: an epidemiological ultrasonographic survey Dig Dis Sci 40 1995 2002 2009
14. N.D. Manton, J. Lipsett, D.J. Moore, G.P. Davidson, A.J. Bourne, and R.T. Couper Non-alcoholic steatohepatitis in children and adolescents Med J Aust 173 2000 476 479
15. S.A. Harrison, and A.M. Diehl Fat and the liver-a molecular overview Sem Gastrointest Dis 13 2002 3 16
16. S. Chitturi, M. Weltman, G.C. Farrell, D. McDonald, J. Kench, and C. Liddle HFE mutations, hepatic iron, and fibrosis: ethnic-specific association of NASH with C282Y but not with fibrotic severity Hepatology 36 2002 142 149
17. S.A. Harrison, D.A. Oliver, S. Torgerson, P. Hayashi, and B. Neuschwander-Tetri NASH: clinical assessment of 501 patients from two separate academic medical centers with validation of a clinical scoring system for advanced hepatic fibrosis Hepatology 34 Suppl 1 2003 511A
18. L. Santos, E.G. Molina, L. Jeffers, R. Reddy, and E. Schiff Prevalence of nonalcoholic steatohepatitis among ethnic groups Gastroenterology 120 2001 A117
19. S.H. Caldwell, D.M. Harris, J.T. Patrie, and E.E. Hespenheide Is NASH under-diagnosed among African-Americans? Am J Gastroenterol 97 2002 1496 1500
20. E.E. Powell, W.G. Cooksley, R. Hanson, J. Searle, J.W. Halliday, and L.W. Powell The natural history of nonalcoholic steatohepatitis: a follow-up study of forty-two patients for up to 21 years Hepatology 11 1990 74 80
21. B.R. Bacon, M.J. Farahvash, C.G. Janney, and B.A. Neuschwander-Tetri Nonalcoholic steatohepatitis: an expanded clinical entity Gastroenterology 107 1994 1103 1109
22. P. Angulo, J.C. Keach, K.P. Batts, and K.D. Lindor Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 1999 1356 1362
23. P. Mofrad, M.J. Contos, M. Haque, C. Sargeant, R.A. Fisher, and V.A. Luketic Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values Hepatology 37 2003 1286 1292
24. L.A. Adams, J. Keach, and K. Lindor Prevalence of autoantibodies and autoimmune hepatitis in nonalcoholic fatty liver disease Hepatology 34 Suppl 1 2003 503A
25. G. Reaven Syndrome X: 10 years after Drugs 58 Suppl 1 1999 75 82
26. R.A. DeFronso, and E. Ferranini Insulin resistance: a multifaceted syndrome responsible for NIDDM, obesity, hypertension, dyslipidemia, and atherosclerotic cardiovascular disease Diabetes Care 14 1991 173 194
27. G. Marchesini, M. Brizi, A.M. Marsell-Labate, G. Bianchi, E. Bugianesi, and A.J. McCullough Association of nonalcoholic fatty liver disease with insulin resistance Am J Med 107 1999 450 455
28. A.J. Sanyal, C. Campbell-Sangert, F. Mirshahi, W.B. Rizzo, M.J. Contos, and R.K. Sterling Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 120 2001 1183 1192
29. G. Pagano, G. Pacini, G. Musso, R. Gambino, F. Mecca, and N. Depetris Non-alcoholic steatohepatitis, insulin resistance, and metabolic syndrome: further evidence for an etiologic association Hepatology 35 2002 367 372
30. S. Chitturi, S. Abeygunasekera, G.C. Farrell, J. Holmes-Walker, J.M. Hui, and C. Fung NASH and insulin resistance: insulin hypersecretion and specific association with insulin resistance syndrome Hepatology 35 2002 373 379
31. P. Marceau, S. Biron, F.S. Hould, S. Marceau, and S. Biron Liver pathology and metabolic syndrome X in severe obesity J Clin Endocrinol Metab 84 1999 1513 1517
32. S. Fargion, M. Mattioli, A.L. Fracanzani, M. Sampietro, D. Tavazzi, and P. Fociani Hyperferritinemia, iron overload, and multiple metabolic alterations identify patients at risk for nonalcoholic steatohepatitis Am J Gastroenterol 96 2001 2448 2455
33. D.K. George, S. Goldwurm, G.A. MacDonald, L.L. Cowley, N.I. Walker, and P.J. Ward Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis Gastroenterology 114 1998 311 318
34. H.L. Bonkovsky, Q. Jawaid, K. Tortorelli, P. LeClair, J. Cobb, and R.W. Lambrecht Non-alcoholic steatohepatitis and iron: ncreased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis J Hepatol 31 1999 421 429
35. Z.M. Younossi, T. Gramlich, B.R. Bacon, C.A. Matteoni, N. Boparai, and R. O'Neill Hepatic iron and nonalcoholic fatty liver disease Hepatology 30 1999 847 850
36. M.H. Mendler, B. Turlin, R. Moirand, A.M. Jouanolle, T. Sapey, and D. Guyder Insulin resistance-associated hepatic iron overload Gastroenterology 117 1999 1155 1163
37. P.H. Hayashi, S.A. Harrison, S. Torgerson, T.A. Perez, T. Nochajski, and M. Russell Cognitive lifetime drinking history in nonalcoholic fatty liver disease: some cases may be alcohol related Am J Gastroenterol 99 2004 76 81
38. S.A. Harrison, S. Kadakia, K.A. Lang, and S. Schenker Nonalcoholic steatohepatitis: what we know in the new millennium Am J Gastroenterol 97 2002 2714 2724
39. M. Graif, M. Yanuka, M. Baraz, A. Blank, M. Mochkovitz, and A. Kessler Quantitative estimation of attenuation in ultrasound video images: correlation with histology in diffuse liver disease Invest Radiol 35 2000 319 324
40. S. Saadeh, Z.M. Younossi, E.M. Remer, T. Gramlich, J.P. Ong, and M. Hurley The utility of radiological imaging in nonalcoholic fatty liver disease Gastroenterology 123 2002 745 750
41. E.M. Brunt, C.G. Janney, A.M. Di Bisceglie, B.A. Neuschwander-Tetri, and B.R. Bacon Nonalcoholic steatohepatitis: a proposal for grading and staging the histologic lesions Am J Gastroenterol 94 1999 2468 2473
42. R.G. Lee Nonalcoholic steatohepatitis: a study of 49 patients Hum Pathol 20 1989 594 598
43. V. Ratziu, P. Giral, F. Charlotte, E. Bruckert, V. Thibault, and I. Theodorou Liver fibrosis in overweight patients Gastroenterology 118 2000 1117 1123
44. S.H. Caldwell, R.H. Swerdlow, E.M. Khan, J.C. Iezzoni, E.E. Hespenheide, and J.K. Parks Mitochondrial abnormalities in non-alcoholic steatohepatitis J Hepatol 31 1999 430 434
45. C.P. Day, and O.F. James Steatohepatitis: a tale of two "hits"? editorial Gastroenterology 114 1998 842 845
46. K.F. Petersen, E.A. Oral, S. Dufour, D. Befroy, C. Ariyan, and C. Yu Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy J Clin Invest 109 2002 1345 1350
47. A. Seppala-Lindroos, S. Vehkavaara, A.M. Hakkinen, T. Goto, J. Westerbacka, and A. Sovijarvi Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men J Clin Endocrinol Metab 87 2002 3023 3028
48. A. Garg, and A. Misra Hepatic steatosis, insulin resistance, and adipose tissue disorders J Clin Endocrinol Metab 87 2002 3019 3022
49. L.M. Kaplan Leptin, obesity, and liver disease Gastroenterology 115 1998 997 1001
50. G.A. Rutter Diabetes: the importance of the liver Curr Biol 10 2000 R736 R738
51. A.R. Saltiel, and C.R. Kahn Insulin signaling and the regulation of glucose and lipid metabolism Nature 414 2001 799 806
52. C. Hug, and H.F. Lodish Diabetes, obesity and acrp30/adiponectin Drug Dis Gen Tech 33 2002 654 662
53. J.R. Zierath, A. Krook, and H. Wallberg-Henriksson Insulin action and insulin resistance in skeletal muscle Diabetologia 43 2000 677 683
54. J.D. Horton, J.L. Goldstein, and M.S. Brown SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver J Clin Invest 109 2002 1125 1131
55. M.H. Cummings, G.F. Watts, A.M. Umpleby, T.R. Hennessy, J.M. Kelly, and N.C. Jackson Acute hyperinsulinemia decreases the hepatic secretion of very-low-density lipoprotein apolipoprotein B-100 in NIDDM Diabetes 44 1995 1059 1065
56. M. Charlton, R. Sreekumar, D. Rasmussen, K. Lindor, and K.S. Nair Apolipoprotein synthesis in nonalcoholic steatohepatitis Hepatology 35 2002 898 904
57. A.R. Mensenkamp, M.J.A. van Luyn, H. van Goor, V. Bloks, F. Apostel, and J. Greeve Hepatic lipid accumulation, altered very low density lipoprotein formation and apolipoprotein E deposition in apolipoprotein E3-Leiden transgenic mice J Hepatol 33 2000 189 198
58. S. Bernard, S. Touzet, I. Personne, V. Lapras, P.J. Bondon, and F. Berthezene Association between microsomal triglyceride transfer protein gene polymorphism and the biological features of liver steatosis in patients with type II diabetes Diabetologia 43 2000 995 999
59. J. Bjorkegren, A. Beigneux, M.O. Bergo, J.J. Maher, and S.G. Young Blocking the secretion of hepatic very low density lipoproteins renders the liver more susceptible to toxin-induced injury J Biol Chem 277 2002 5476 5483
60. R.B. Ceddia, H.A. Koistinen, J.R. Zierath, and G. Sweeney Analysis of paradoxical observations on the association between leptin and insulin resistance FASEB J 16 2002 1163 1176
61. I. Leclercq, A. Enriquez, and G.C. Farrell Rapid reversal of liver steatosis by leptin on ob/ob mice [abstract] J Gastroenterol Hepatol 13 Suppl 1998 188A
62. N. Barzilai, J. Wang, D. Massilon, P. Vuguin, M. Hawkins, and L. Rosetti Leptin selectively decreases visceral adiposity and enhances insulin action J Clin Invest 100 1997 3105 3110
63. M.L. Reitman, E. Arioglu, O. Gavrilova, and S.I. Taylor Lipoatrophy revisited Trends Endocrinol Metab 11 2000 410 416
64. B. Cohen, D. Novick, and M. Rubinstein Modulation of insulin activities by leptin Science 274 1996 185 188
65. G. Muller, J. Ertl, M. Gerl, and G. Preibisch Leptin impairs metabolic actions of insulin in isolated rat adipocytes J Biol Chem 272 1997 10585 10593
66. R.V. Considine, M.K. Sinha, M.L. Heiman, A. Kriauciunas, T.W. Stephens, and M.R. Nyce Serum immunoreactive leptin concentrations in normal weight and obese humans N Engl J Med 334 1996 292 295
67. S. Chitturi, G. Farrell, L. Frost, A. Kriketos, R. Lin, and C. Fung Serum leptin in NASH correlates with hepatic steatosis but not fibrosis: a manifestation of lipotoxicity Hepatology 36 2002 403 409
68. A. Uygun, A. Kadayifci, Z. Yesilova, A. Erdil, H. Yaman, and M. Saka Serum leptin levels in patients with nonalcoholic steatohepatitis Am J Gastroenterol 95 2000 3584 3589
69. N. Chalasani, D.W. Crabb, O.W. Cummings, P.Y. Kwo, A. Asghar, and P.K. Pandya Does leptin play a role in the pathogenesis of human nonalcoholic steatohepatitis? Am J Gastroenterol 98 2003 2771 2776
70. G.S. Hotamisligil, P. Peraldi, A. Budavari, R. Ellis, M.F. White, and B.M. Spiegelman IRS-1 mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha- and obesity-induced insulin resistance Science 271 1996 665 668
71. N. Maeda, I. Shimomura, K. Kishida, H. Nichizawa, M. Matsuda, and H. Nagaretani Diet-induced insulin resistance in mice lacking adiponectin/ACRP30 Nat Med 8 2002 731 737
72. A. Xu, Y. Wang, H. Keshaw, L.Y. Xu, K.S. Lam, and G.J. Cooper The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice J Clin Invest 112 2003 91 100
73. R. Zanger, and R. Novak Effects of fatty acids and ketone bodies on cytochromes p4502B, 4A, 2E1 expression in primary cultured rat hepatocytes Arch Biochem Biophys 337 1997 217 224
74. I.A. Leclercq, G.C. Farrell, J. Field, D.R. Bell, F.J. Gonazle, and G.R. Robertson CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis J Clin Invest 105 2000 1067 1075
75. M.D. Weltman, G.C. Farrell, and P. Hall Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis Hepatology 27 1998 128 133
76. M. Yuan, N. Konstantopoulos, J. Lee, L. Hansen, Z.W. Li, and M. Karin Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of IKKβ Science 293 2001 1673 1677
77. P.A. Baeuerle, and T. Henkel Function and activation of NF-κB in the immune system Annu Rev Immunol 12 1994 141 179
78. J. Crespo, A. Cayon, P. Fernadez-Gil, M. Hernandez-Guerra, M. Mayorga, and A. Dominguez-Diez Gene expression of TNF-α and TNF receptors, p55 and p75 J Hepatol 34 2001 1158 1163
79. S. Loffreda, S.Q. Yang, H.Z. Lin, C.L. Karp, M.L. Brengman, and D.J. Wang Leptin regulates proinflammatory immune responses FASEB J 12 1998 57 65
80. S.Q. Yang, H.Z. Lin, M.D. Lane, M. Clemens, and A.M. Diehl Obesity increases sensitivity to endotoxin liver injury: implications for pathogenesis of steatohepatitis Proc Natl Acad Sci USA 94 1997 2557 2562
81. D. Pessayre, A. Berson, B. Fromenty, and A. Mansouri Mitochondria in steatohepatitis Sem Liv Dis 21 2001 57 69
82. S. Yang, H. Zhu, and Y. Li Mitochondrial adaptations to obesity-related oxidative stress Arch Biochem Biophys 378 2000 259 268
83. D. Acosta, and D.G. Wenzel Injury produced by free fatty acids to lysosomes and mitochondria in cultured heart muscle and endothelial cells Atherosclerosis 20 1974 417 426
84. K.D. Chavin, S. Yang, H.Z. Lin, J. Chatham, V.P. Chacko, and J.B. Hoek Obesity induces expression of UCP-2 in hepatocytes and promotes liver ATP depletion J Biol Chem 274 1999 5692 5700
85. H. Cortez-Pinto, J. Chatham, V. Chacko, C. Arnold, A. Rashid, and A.M. Diehl Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis-a pilot study JAMA 282 1999 1659 1664
86. S.C. Lu, L. Alvarez, Z.Z. Huang, L. Chen, W. An, and F.J. Corrales Methionine adenosyltransferase 1A knockout mice are predisposed to liver injury and exhibit increased expression of genes involved in proliferation Proc Natl Acad Sci USA 98 2001 5560 5565
87. M.L. Martinez-Chantar, F.J. Corrales, L.A. Martinez-Cruz, E.R. Garcia-Trevijano, Z.Z. Huang, and L. Chen Spontaneous oxidative stress and liver tumors in mice lacking methionine adenosyltransferase 1A FASEB 16 2002 1292 1294
88. E. Santamaria, M.A. Avila, M.U. Latasa, A. Rubio, A. Martin-Duce, and S.C. Lu Functional proteomics of nonalcoholic steatohepatitis: mitochondrial proteins as targets of s-adenosylmethionine Proc Natl Acad Sci USA 100 2003 3065 3070
89. M. Perez-Carreras, P. Del Hoyo, M.A. Martin, J.C. Rubio, A. Marin, and G. Castellano Defective hepatic mitochondrial respiratory chain in patients with nonalcoholic steatohepatitis Hepatology 38 2003 999 1007
90. A.E. Feldstein, A. Canbay, P. Angulo, M. Taniai, L.J. Burgart, and K.D. Lindor Hepatocyte apoptosis and fas expression are prominent features of human nonalcoholic steatohepatitis Gastroenterology 125 2003 437 443
91. S.L. Friedman The cellular basis of hepatic fibrosis. Mechanisms and treatment strategies N Engl J Med 328 1993 1828 1833
92. M. Parola, and G. Robino Oxidative stress-related molecules and liver fibrosis J Hepatol 35 2001 297 306
93. N. Nieto, S.L. Friedman, P. Greenwel, and A.I. Cederbaum CYP2E1-mediated oxidative stress induces collagen type I expression in rat hepatic stellate cells Hepatology 30 1999 987 996
94. G. Svegliati-Baroni, S. Saccomanno, H. van Goor, P. Jansen, A. Benedetti, and H. Moshage Involvement of reactive oxygen species and nitric oxide radicals in activation and proliferation of rat hepatic stellate cells Liver 21 2001 1 12
95. M.R. Teli, O.F. James, A.D. Burt, M.K. Bennett, and C.P. Day The natural history of nonalcoholic fatty liver: a follow-up study Hepatology 22 1995 1714 1719
96. C.A. Matteoni, Z.M. Younossi, T. Gramlich, N. Bopari, Y.C. Liu, and A.J. Mc Cullough Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity Gastroenterology 116 1999 1413 1419
97. S.A. Harrison, S. Torgerson, and P. Hayashi Natural history of NASH: a clinical histopathologic study Am J Gastroenterol 98 2003 2042 2047
98. J.M. Hui, J.G. Kench, S. Chitturi, A. Sud, G.C. Farrell, and K. Byth Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C Hepatology 38 2003 420 427
99. M. Charlton, P. Kasparova, S. Weston, K. Lindor, Y. Maor-Kendler, and R.H. Wiesner Frequency of nonalcoholic steatohepatitis as a cause of advanced liver disease Liver transplantation 7 2001 608 614
100. S.H. Caldwell, D.H. Oelsner, J.C. Iezzoni, E.E. Hespenheide, E.H. Battle, and C.J. Driscoll Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease Hepatology 29 1999 664 669
101. A. Poonawala, S.P. Nair, and P.J. Thulavath Prevalence of obesity and diabetes in patients with cryptogenic cirrhosis: a case-control study Hepatology 32 2000 689 692
102. M.J. Contos, W. Cales, R.K. Sterling, V.A. Luketic, M.L. Shiffman, and A.S. Mills Development of non-alcoholic fatty liver disease after orthotopic liver transplantation for cryptogenic cirrhosis Liver Transplantation 7 2001 363 373
103. D.F. Schafer, and M.F. Sorrell Hepatocellular carcinoma Lancet 33 1999 1253 1257
104. H.P. Cotrim, R. Parana, E. Braga, and L. Lya Nonalcoholic steatohepatitis and hepatocellular carcinoma: natural history? Am J Gastroenterol 95 2000 3018 3019
105. M. Shimada, E. Hashimoto, M. Taniai, K. Hasegawa, H. Okuda, and N. Hayashi Hepatocellular carcinoma in patients with non-alcoholic steatohepatitis J Hepatol 37 2002 154 160
106. E. Bugianesi, N. Leone, E. Vanni, G. Marchesini, F. Brunello, and P. Carucci Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma Gastroenterology 123 2002 134 140
107. J.A. Marrero, R.J. Fontana, G.L. Su, H.S. Conjeevaram, D.M. Emick, and A.S. Lok NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States Hepatology 36 2002 1349 1354
108. J.M. Hui, J.G. Kench, S. Chitturi, A. Sud, G.C. Farrell, and K. Byth Long-term outcomes of cirrhosis in nonalcoholic steatohepatitis compared with hepatitis C Hepatology 38 2003 420 427
109. T. Ueno, H. Sagawara, K. Sujaka, O. Hashimoto, R. Tsuji, and S. Tamaki Therapeutic effects of restricted diet and exercise in obese patients with fatty liver J Hepatol 27 1997 103 107
110. P. Rozental, C. Biava, H. Spencer, and H.J. Zimmerman Liver morphology and function tests in obesity and during total starvation Am J Dig Dis 12 1967 198 208
111. T. Andersen, C. Gluud, M.B. Franzmann, and P. Christoffersen Hepatic effects of dietary weight loss in morbidly obese patients J Hepatol 12 1991 224 229
112. M. Palmer, and F. Schaffner Effect of weight reduction on hepatic abnormalities in overweight patients Gastroenterology 99 1990 1408 1413
113. E.J. Drenick, F. Simmons, and J. Murphy Effect on hepatic morphology of treatment of obesity by fasting, reducing diets, and small bowel bypass N Engl J Med 282 1970 829 834
114. A.M. Heck, J.A. Yanovski, and K.A. Calis Orlistat, a new lipase inhibitor for the management of obesity Pharmacotherapy 20 2000 270 279
115. S.A. Harrison, S. Ramrakhiani, E.M. Brunt, M.A. Anbari, C. Cortese, and B.R. Bacon Orlistat in the treatment of NASH: a case series Am J Gastroenterol 98 2002 926 930
116. S.A. Harrison, C. Fincke, and D. Helinski Orlistat treatment in obese, non-alcoholic patients: a pilot study [abstract] Hepatology 36 2002 406A
117. F.H. Luyckx, C. Desaive, A. Thiry, W. Dewe, A.J. Scheen, and J.E. Gielen Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty Int J Obes Relat Metab Disord 22 1998 222 226
118. I. Ranlov, and F. Hardt Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity Digestion 47 1990 208 214
119. J.M. Lehmann, L.B. Moore, T.A. Smith-Oliver, W.O. Wilkison, T.M. Wilson, and S.A. Kliewer An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Biol Chem 270 1995 12953 12956
120. A.B. Mayerson, R.S. Hundal, S. Dufour, V. Lebon, D. Befroy, and G.W. Cline The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes Diabetes 51 2002 797 802
121. L.G.D. Fryer, A. Parbu-Patel, and D. Carling The anti-diabetic drugs rosiglitazone and metformin stimulate AMP-activated protein kinase through distinct signaling pathways J Biol Chem 277 2002 25226 25232
122. Y.-B. Kim, T.P. Ciaraldi, A. Kong, A. Kim, D. Kim, and N. Chu Troglitazone but not metformin restores insulin-stimulated phosphoinositide 3-kinase activity and increases p110β protein levels in skeletal muscle of type 2 diabetic subjects Diabetes 51 2002 443 448
123. A. Galli, D.W. Crabb, E. Ceni, R. Salzano, T. Mello, and G. Svegliati-Baroni Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro Gastroenterology 122 2002 1924 1940
124. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, C. Sponseller, K. Hampton, and B.R. Bacon Interim results of a pilot study demonstrating the early effects of the PPAR-γ ligand rosiglitazone on insulin sensitivity, aminotransferases, hepatic steatosis and body weight in patients with non-alcoholic steatohepatitis J Hepatol 38 2003 434 440
125. B.A. Neuschwander-Tetri, E.M. Brunt, K.R. Wehmeier, D. Oliver, and B.R. Bacon Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-γ ligand rosiglitazone Hepatology 38 2003 1008 1017
126. K. Promrat, G. Lutchman, G.I. Uwaifo, R.J. Freedman, A. Soza, and T. Hellar A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis Hepatology 39 2004 188 196
127. N. Musi, M.F. Hirshman, J. Nygren, M. Svanfeldt, P. Bavenholm, and O. Rooyackers Metformin increases AMP-activated protein kinase activity in skeletal muscle of subjects with type 2 diabetes Diabetes 51 2002 2074 2081
128. G. Zhou, R. Myers, Y. Li, Y. Chen, X. Shen, and J. Fenyk-Melody Role of AMP-activated protein kinase in mechanism of metformin action J Clin Invest 108 2001 1167 1174
129. H.Z. Lin, S. Yang, C. Chuckaree, F. Kuhajda, G. Ronnet, and A.M. Diehl Metformin reverses fatty liver disease in obese, leptin-deficient mice Nat Med 6 2000 998 1003
130. G. Marchesini, M. Brizi, G. Blanchi, S. Tomassetti, M. Zoli, and N. Melchionda Metformin in non-alcoholic steatohepatitis Lancet 358 2001 893 894
131. J.E. Lavine Vitamin E treatment of non-alcoholic steatohepatitis in children: a pilot study J Pediatr 136 2000 734 738
132. T. Hasegawa, M. Yoneda, K. Nakamura, I. Makino, and A. Terano Plasma transforming growth factor-β1 level and efficacy of α-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study Aliment Pharmacol 15 2001 1667 1672
133. S.A. Harrison, S. Torgerson, J. Ward, P. Hayashi, and S. Schenker Vitamin E and Vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis Am J Gastroenterol 98 2003 2485 2490
134. S.C. Lu S-adenosylmethionine Int J Biochem Cell Bio 32 2000 391 395
135. M.F. Abdelmalek, P. Angulo, R.A. Jorgensen, P.B. Sylvestre, and K.D. Lindor Betaine, a promising new agent for patients with nonalcoholic steatohepatitis: results of a pilot study Am J Gastroenterol 96 2001 2711 2717
136. M. Basaranoglu, O. Acbay, and A. Sonsuz A controlled trial of gemfibrozil in the treatment of patients with nonalcoholic steatohepatitis J Hepatol 31 1999 384
137. J.C. Horlander, P.Y. Kwo, and O.W. Cummings Atorvastatin for the treatment of NASH Gastroenterology 120 2001 A544
138. K.D. Lindor, K.V. Kowdley, E.J. Heathcote, M.E. Harrison, R. Jorgensen, and P. Angulo Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial Hepatology 39 3 2004 Mar 770 778